ABO-incompatible living donor liver transplantation without graft local infusion and splenectomy.

ABSTRACT:

Background

Graft local infusion and splenectomy in ABO-incompatible (ABO-I) living donor liver transplantation (LDLT) are associated with high rates of operative complications.

Methods

Consecutive ABO-I LDLT patients treated at the National Cancer Centre between January 2012 and February 2013 were identified. The protocol for ABO-I LDLT at the study centre included the administration of rituximab (300 mg/m(2)) at 2 weeks preoperatively, followed by plasma exchanges (target isoagglutinin titre: ≤ 1:8), basiliximab (20 mg on the day of surgery and on postoperative day 4), and i.v. immunoglobulin (0.8 g/kg on postoperative days 1 and 4) without graft local infusion or splenectomy.

Results

Fifteen patients (11 men and four women) who underwent transplantation for liver ci

SUBMITTER: Lee SD 

PROVIDER: S-EPMC4159453 | biostudies-literature | 2014 Sep

REPOSITORIES: biostudies-literature